Navigation Links
Vanda Presents Phase III Iloperidone Efficacy Data
Date:12/12/2007

lease contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding Vanda's plans for its product candidates. Words such as, but not limited to, "look forward to," "believe," "expect," "anticipate," "estimate," "intend," "plan," "targets," "likely," "will," "would," "should," and "could," and similar expressions or words identify forward-looking statements. Such forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. Vanda is at an early stage of development and may not ever have any products that generate significant revenue. Important factors that could cause actual results to differ materially from those reflected in Vanda's forward-looking statements include, among others, a failure of Vanda's product candidates to be demonstrably safe and effective, a failure to obtain regulatory approval for the company's products or to comply with ongoing regulatory requirements, a lack of acceptance of Vanda's product candidates in the marketplace, a failure of the company to become or remain profitable, Vanda's inability to obtain the capital necessary to fund its research and development activities, a loss of any of the company's key scientists or management personnel, and other factors that are described in the "Risk Factors" section (Part II, Item 1A) of Vanda's report on Form 10-Q for the quarter ended September 30, 2007 (File No. 000-51863). No forward-looking statements can be guaranteed and actual results may differ materially from such statements. The information in this release is provided only as of the date of this release, and Vanda undertakes no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.


'/>"/>
SOURCE Vanda Pharmaceuticals Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Vanda Pharmaceuticals Submits Iloperidone New Drug Application
2. Vanda Pharmaceuticals Reports Third Quarter 2007 Results
3. Vanda Pharmaceuticals Receives FDA Acceptance of Iloperidone New Drug Application
4. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
5. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
6. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
7. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
8. CEL-SCI Presents Data for CEL-1000 as a Vaccine Adjuvant with Recombinant Hepatitis B Virus Protein
9. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
10. Targanta Presents First Data Demonstrating In Vitro Activity and In Vivo Efficacy of Prodrugs in Osteomyelitis Models
11. Wyeth Presents Phase 3 Fracture Data for Bazedoxifene, an Investigational Therapy for Osteoporosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... PLAINFIELD, N.J. , Aug. 1, 2014  PTC ... that on July 31, 2014 it approved non-statutory stock ... its common stock to seven new employees. The awards ... as a component of our new hires, employment compensation. ... Compensation Committee on July 31, 2014 and are being ...
(Date:8/1/2014)... , Aug. 1, 2014  With monumental health ... to speak a second language. Clinical efficacy is no ... established under the ACA like PCORI are directing roughly ... variety of new entities and environments, the federal healthcare ... the new language of outcomes and managed markets to ...
(Date:8/1/2014)... and NEW YORK , ... VRX) and Pershing Square Capital Management, L.P. today responded ... Inc. (NYSE: AGN ) in California.  The ... regarding the tender offer rules.  Allergan,s ... to interfere with shareholders, efforts to call a special ...
Breaking Medicine Technology:PTC Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) 2Pharmaceuticals Learning the Language of the New Healthcare Landscape 2Pharmaceuticals Learning the Language of the New Healthcare Landscape 3Valeant Pharmaceuticals And Pershing Square Respond To Frivolous Allergan Lawsuit 2Valeant Pharmaceuticals And Pershing Square Respond To Frivolous Allergan Lawsuit 3Valeant Pharmaceuticals And Pershing Square Respond To Frivolous Allergan Lawsuit 4Valeant Pharmaceuticals And Pershing Square Respond To Frivolous Allergan Lawsuit 5Valeant Pharmaceuticals And Pershing Square Respond To Frivolous Allergan Lawsuit 6
... Pharmaceuticals International, Inc. (NYSE: VRX ) (TSX: VRX) ... ) and Cephalon, Inc. (NASADQ: CEPH) on their announcement that ... to the news, Valeant has withdrawn its consent solicitation. ... for Cephalon stockholders and we are pleased that Teva has ...
... Solutions, Inc. (OTCQB: VHSLD) announced that it will begin ... Financial Industry Regulatory Authority has approved a change in ... ticker change has gone into effect for the trading ... the "D" will be removed from the ticker symbol ...
Cached Medicine Technology:Valeant Pharmaceuticals Congratulates Teva and Cephalon on Their Transaction 2Vertical Health Solutions to Begin Doing Business as OnPoint Medical Diagnostics and Announces Completion of Symbol Change 2
(Date:8/1/2014)... of Medicine in St. Louis helps explain why brain ... more harmful than similar tumors in females. For example, ... twice as often in males, who suffer greater cognitive ... , The researchers found that retinoblastoma protein (RB), a ... active in male brain cells than in female brain ...
(Date:8/1/2014)... Gray HealthDay Reporter FRIDAY, Aug. ... in manufacturing jobs may have significantly less endurance than those who ... 32 people -- half were obese, half were of normal weight ... about 60 percent longer. Obesity also was associated with less ... Being older -- 50 to 65 years of age -- neither ...
(Date:8/1/2014)... Aug. 1, 2014 (HealthDay News) -- Almost 140 ... school transportation in the United States. But ... bus-related catastrophes, Dawne Gardner, injury prevention coordinator at ... Center, said in a medical center news release. ... returning to school, it,s important for parents and ...
(Date:8/1/2014)... Summer is here, and with it comes the ... and they can be a pain for dogs. Animal Emergency ... their customers get rid of ticks and prevent them completely. ... the summer, which is why they are so active during ... woodland areas and carry a number of diseases, including lyme ...
(Date:8/1/2014)... bisexual, and transgender individuals who want to conceive a ... their heterosexual and cisgendered peers, such as reduced fertility, ... and legal challenges to become parents. A comprehensive review ... is presented in the article " LGBT Assisted Reproduction: ... LGBT Health , a peer-reviewed journal from ...
Breaking Medicine News(10 mins):Health News:Study reveals one reason brain tumors are more common in men 2Health News:Obesity Might Slow You Down at Work 2Health News:Obesity Might Slow You Down at Work 3Health News:Expert Offers School Bus Safety Tips 2Health News:Tis the Season for Tick Prevention 2Health News:Advances in assisted reproduction create more options and new legal issues for LGBT couples 2
... AMSTERDAM, The Netherlands, June 19 Agendia BV ... headquarters yesterday,at Amsterdam,s Science Park at Watergraafsmeer, Kruislaan ... Rene Bernards, Chief Scientific,Officer at Agendia and the ... the Honourable Mrs. Maria van der Hoeven, Minster ...
... database, AUBURN HILLS, Mich., June 19 ... on-demand software for the manufacturing,enterprise, today announced ... using Plexus Online to facilitate collaboration,coordination and ... academic., (Logo: http://www.newscom.com/cgi-bin/prnh/20070627/CLW071LOGO ), ...
... WASHINGTON, June 19 The Corn Refiners Association ... (AMA) that,concluded "high fructose corn syrup does not ... decision was issued June 17 in Chicago,at the ... organizations,principal policy-making body., "This science-based decision by ...
... if the emotional and financial impact of flood damage ... H. James Wedner, M.D., professor of medicine and chief ... University School of Medicine in St. Louis, says after ... grounds for mold growth, which can cause allergic reactions ...
... and those with lower incomes, study finds , , ... you at a higher risk for developing anxiety and ... 40 hours a week or less had a 9 ... 12.5 percent of their counterparts who worked overtime showed ...
... for people with asthma, MS, scientists say , , ... cellular proteins that may be key to certain autoimmune ... , The findings, performed so far only in mice, ... human diseases that are mediated by immune system T-cells. ...
Cached Medicine News:Health News:Agendia Expands Laboratory Capacity at New Amsterdam Headquarters to Meet Increasing Demand for Services Worldwide 2Health News:Plexus Online Enables Business-Government-Academic Collaboration for Advanced Technology Institute 2Health News:Plexus Online Enables Business-Government-Academic Collaboration for Advanced Technology Institute 3Health News:Plexus Online Enables Business-Government-Academic Collaboration for Advanced Technology Institute 4Health News:Allergy expert has advice for flood victims 2Health News:Allergy expert has advice for flood victims 3Health News:Autoimmune Disease Treatment May Not Dampen Immune System 2Health News:Autoimmune Disease Treatment May Not Dampen Immune System 3Health News:Autoimmune Disease Treatment May Not Dampen Immune System 4
ELISA kit for the quantitative determination of autoantibodies to thyroid peroxidase (TPO) in serum...
ELISA kit for the quantitative determination of autoantibodies to thyroglobulin in serum....
... the most potent, naturally secreted estrogen and ... ovary [1]. In the ovary, estradiol is ... a less potent estrogen derived from androstenedione. ... body tissues. In men, small amounts of ...
... troponin I (cTnI) has been useful in ... Emergency Departments (ED) with chest pain. 18-20 ... when blood levels of sensitive and specific ... isoenzyme of creatine kinase (CK-MB), and myoglobin, ...
Medicine Products: